NGL Fine-Chem (NGLFINE) Fundamentals 2026 — P/E 41.9x, Revenue Analysis | SniperIQ
NGL Fine-Chem (NGLFINE) is a India-listed Healthcare company in Drug Manufacturers - General with a market capitalization of ₹2,012 Crore, trading at ₹3256.20 on the NSE. This SniperIQ fundamentals page covers NGL Fine-Chem's valuation (P/E 41.9x, P/B 6.1x), profitability (net margin 9.6%), revenue (₹501 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is NGL Fine-Chem's market cap?
NGL Fine-Chem (NGLFINE) has a market capitalization of approximately ₹2,012 Crore, trading at ₹3256.20 on the NSE. Market cap moves with the live share price.
What is NGL Fine-Chem's P/E ratio?
NGL Fine-Chem's trailing twelve-month P/E ratio is 41.9x, with a price-to-book (P/B) of 6.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is NGL Fine-Chem?
NGL Fine-Chem runs a net profit margin of 9.6%, a gross margin of 43.4%, and an operating margin of 10.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does NGL Fine-Chem generate?
NGL Fine-Chem reported revenue of ₹501 Crore for fiscal year 2026, with net income of ₹48 Crore and earnings per share (EPS) of 77.9. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does NGL Fine-Chem pay a dividend?
NGL Fine-Chem offers a trailing dividend yield of about 0.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is NGL Fine-Chem financially healthy?
NGL Fine-Chem carries a debt-to-equity ratio of 0.33x and a current ratio of 1.84x, with a market beta of 0.62. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is NGL Fine-Chem a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For NGL Fine-Chem (NGLFINE) the key facts are: market cap ₹2,012 Crore, P/E 41.9x, revenue ₹501 Crore, 52-week range 1175.5-3329. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track NGL Fine-Chem's full fundamentals live
Get NGL Fine-Chem's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.